Abstract
Incidence and risk of eribulin mesylate related hematologic toxicity
Highlights
Eribulin mesylate, a macrocyclic ketone analogue of Halichondrin B, is a completely synthetic, microtubule dynamics inhibitor [1, 2]
This is the first meta-analysis focused on hematologic toxicities associated with eribulin mesylate
Our data revealed that the overall incidences of eribulin related all-grade and high-grade hematologic toxicities were: neutropenia, 56% and 39%; leucopenia, 44% and 21%; anemia, 33% and 2%, febrile neutropenia, 5% and 5%; and thrombocytopenia, 12% and 12%
Summary
Eribulin mesylate (hereafter referred as “eribulin”), a macrocyclic ketone analogue of Halichondrin B, is a completely synthetic, microtubule dynamics inhibitor [1, 2]. Preclinical evidence further reveals that eribulin suppresses the development of tumor by inhibiting mitotic spindle formation [3], reversing phenotype from epithelial-mesenchymal transition state to mesenchymal-epithelial transition state [4], and remodeling tumor vasculature [5]. Eribulin has been approved by the US Food and Drug Administration (FDA) for the treatment of breast cancer (BC) [6], and recently, liposarcoma [7]. Due to its novel mechanism, eribulin treatment is often associated with a distinct profile of adverse events. Here we conducted a metaanalysis of available clinical data to calculate the overall incidence and relative risk of developing hematologic toxicities, namely neutropenia, leucopenia, anemia, febrile neutropenia, and thrombocytopenia, in cancer patients treated with eribulin
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
